BioCryst Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.14) Per Share, HC Wainwright Forecasts (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.16). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.51) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at $0.43 EPS.

Several other research firms have also recently commented on BCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. JMP Securities raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $5.34 on Thursday. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.99 and a beta of 1.96. The company’s 50 day simple moving average is $4.89 and its two-hundred day simple moving average is $5.45. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. During the same period in the prior year, the business posted ($0.28) earnings per share. The business’s quarterly revenue was up 34.9% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BCRX. Braidwell LP increased its holdings in BioCryst Pharmaceuticals by 92.1% in the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock valued at $37,970,000 after purchasing an additional 2,571,100 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 15.4% in the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after buying an additional 2,371,401 shares in the last quarter. Norges Bank purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $13,278,000. Deerfield Management Company L.P. Series C lifted its stake in BioCryst Pharmaceuticals by 148.6% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after acquiring an additional 1,964,000 shares in the last quarter. Finally, Avoro Capital Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 13.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.